Biofrontera Inc. Cash Flow Statement
BFRI|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Biofrontera Inc. used $10M in operating cash flow and negative free cash flow of $10M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$17.8M | -$20.1M | -$640.0K | -$37.7M | -$11.0M |
| Depreciation & Amortization | $421.0K | $600.0K | $101.0K | $122.0K | $144.0K |
| Operating Cash Flow | -$10.3M | -$24.9M | -$16.2M | -$26.7M | -$12.4M |
| Capital Expenditures | $10.0K | $5.0K | $38.0K | - | - |
| Free Cash Flow | -$10.3M | -$24.9M | -$16.2M | - | - |
| FCF Margin | -27.5% | -73.1% | -56.6% | - | - |